<!doctype html><html><head><meta charset=utf-8><title>Omega-3 helps NAFLD and other liver problems</title>
<link rel=stylesheet href="/css/main.css?v=1748176441"><link rel=stylesheet href="/css/pagination.css?v=1748176441"><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css><script src=https://unpkg.com/lunr/lunr.js></script><script src=https://cdn.jsdelivr.net/npm/pako@2.1.0/dist/pako.min.js></script><script src="/js/search.js?v=1748176441"></script></head><body><div class=top-nav><div class=home-icon><a href=/ title="Go to Home Page"><svg viewBox="0 0 576 512" width="28" height="28"><path d="M575.8 255.5c0 18-15 32.1-32 32.1h-32l.7 160.2c0 2.7-.2 5.4-.5 8.1V472c0 22.1-17.9 40-40 40H456c-1.1.0-2.2.0-3.3-.1-1.4.1-2.8.1-4.2.1H416 392c-22.1.0-40-17.9-40-40V448 384c0-17.7-14.3-32-32-32H256c-17.7.0-32 14.3-32 32v64 24c0 22.1-17.9 40-40 40H160 128.1c-1.5.0-3-.1-4.5-.2-1.2.1-2.4.2-3.6.2H104c-22.1.0-40-17.9-40-40V360c0-.9.0-1.9.1-2.8V287.6H32c-18 0-32-14-32-32.1.0-9 3-17 10-24L266.4 8c7-7 15-8 22-8s15 2 21 7L564.8 231.5c8 7 12 15 11 24z"/></svg></a></div><div class=search-container><div class=search-icon><i class="fas fa-search"></i></div><input type=text id=search-input placeholder=Search... disabled><div id=suggestions class=search-suggestions style=display:none></div><ul id=search-results style=display:none></ul><div id=search-results-panel class=search-results-panel><div class=results-header>Search Results</div><ul id=search-results-panel-list class=results-list></ul></div></div></div><div class=container><div class="content content-full-width" role=main><article><h1>Omega-3 helps NAFLD and other liver problems</h1><time>December 13, 2024</time><nav id=TableOfContents><ul><li><ul><li><ul><li><a href=#omega-3-intake-is-associated-with-liver-disease-protection>Omega-3 intake is associated with liver disease protection</a></li></ul></li></ul></li></ul></nav><hr><h4 id=omega-3-intake-is-associated-with-liver-disease-protection>Omega-3 intake is associated with liver disease protection</h4><p>Front. Public Health, Volume 11 - 2023 | <a href=https://doi.org/10.3389/fpubh.2023.1192099>https://doi.org/10.3389/fpubh.2023.1192099</a></p><p>\r\nMara Sophie VellMara Sophie Vell1Kate Townsend CreasyKate Townsend Creasy2Eleonora ScorlettiEleonora Scorletti3Katharina Sophie Seeling Katharina Sophie Seeling1 Leonida Hehl Leonida Hehl1Miriam Daphne RendelMiriam Daphne Rendel1Kai Markus Schneider&amp;#x;Kai Markus Schneider1†Carolin Victoria Schneider, &amp;#x;Carolin Victoria Schneider1,3,4*†</p><p>1Department of Medicine III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany</p><p>2Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA, United States</p><p>3Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States</p><p>4The Institute for Translational Medicine and Therapeutics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States</p><img src=https://d1bk1kqxc0sym.cloudfront.net/attachments/webp/reduced-liver-disease-if-omega-3.webp alt=image width=500><p>Background: Non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease are among the most common liver diseases worldwide, and there are currently no Food and Drug Administration (FDA)-approved treatments. Recent studies have focused on lifestyle changes to prevent and treat NAFLD. Omega-3 supplementation is associated with improved outcomes in patients with chronic liver disease. However, it is unclear whether Omega-3 supplementation can prevent the development of liver disease, particularly in individuals at an increased (genetic) risk.</p><p>Methods: In this UK Biobank cohort study, we established a multivariate cox proportional hazards model for the risk of incident liver disease during an 11 year follow up time. We adjusted the model for diabetes, prevalent cardiovascular disorders, socioeconomic status, diet, alcohol consumption, physical activity, medication intake (insulin, biguanides, statins and aspirin), and baseline characteristics.</p><p>Results: Omega-3 supplementation reduced the risk of</p><ul><li>incident liver disease (HR = 0.716; 95% CI: 0.639, 0.802; p = 7.6 × 10−9).</li></ul><p>This protective association was particularly evident for</p><ul><li><p>alcoholic liver disease (HR = 0.559; 95% CI: 0.347, 0.833; p = 4.3 × 10−3),</p></li><li><p>liver failure (HR = 0.548; 95% CI: 0.343, 0.875; p = 1.2 × 10−2), and</p></li><li><p>non-alcoholic liver disease (HR = 0.784; 95% CI: 0.650, 0.944; p = 1.0 × 10−2).</p></li></ul><p>Interestingly, we were able to replicate the association with reduced risk of NAFLD in a subset with liver MRIs (HR = 0.846; 95% CI: 0.777, 0.921; p = 1.1 × 10−4). In particular, women benefited from Omega-3 supplementation as well as heterozygous allele carriers of the liver-damaging variant PNPLA3 rs738409.</p><p>Conclusions: Omega-3 supplementation may reduce the incidence of liver disease. Our study highlights the potential of personalized treatment strategies for individuals at risk of metabolic liver disease. Further evaluation in clinical trials is warranted before Omega-3 can be recommended for the prevention of liver disease.</p><p><strong><i class="fas fa-file-pdf" style=margin-right:.3em></i><a href=https://d1bk1kqxc0sym.cloudfront.net/attachments/pdf/omega-3-liver-compresspdf.pdf>Download the PDF from VitaminDWiki</a></strong></p><pre style=background-color:#e0e0e0;white-space:pre-wrap>
<code class=language-text>
Markdown:
--------
{{&lt; toc &gt;}}

---

#### Omega-3 intake is associated with liver disease protection

Front. Public Health, Volume 11 - 2023 | https://doi.org/10.3389/fpubh.2023.1192099

\r\nMara Sophie VellMara Sophie Vell1Kate Townsend CreasyKate Townsend Creasy2Eleonora ScorlettiEleonora Scorletti3Katharina Sophie Seeling Katharina Sophie Seeling1 Leonida Hehl Leonida Hehl1Miriam Daphne RendelMiriam Daphne Rendel1Kai Markus Schneider&amp;#x;Kai Markus Schneider1†Carolin Victoria Schneider, &amp;#x;Carolin Victoria Schneider1,3,4*†

1Department of Medicine III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany

2Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA, United States

3Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States

4The Institute for Translational Medicine and Therapeutics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States

&lt;img src=&quot;https://d1bk1kqxc0sym.cloudfront.net/attachments/webp/reduced-liver-disease-if-omega-3.webp&quot; alt=&quot;image&quot; width=&quot;500&quot;&gt;

Background: Non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease are among the most common liver diseases worldwide, and there are currently no Food and Drug Administration (FDA)-approved treatments. Recent studies have focused on lifestyle changes to prevent and treat NAFLD. Omega-3 supplementation is associated with improved outcomes in patients with chronic liver disease. However, it is unclear whether Omega-3 supplementation can prevent the development of liver disease, particularly in individuals at an increased (genetic) risk.

Methods: In this UK Biobank cohort study, we established a multivariate cox proportional hazards model for the risk of incident liver disease during an 11 year follow up time. We adjusted the model for diabetes, prevalent cardiovascular disorders, socioeconomic status, diet, alcohol consumption, physical activity, medication intake (insulin, biguanides, statins and aspirin), and baseline characteristics.

Results: Omega-3 supplementation reduced the risk of 

* incident liver disease (HR = 0.716; 95% CI: 0.639, 0.802; p = 7.6 × 10−9). 

This protective association was particularly evident for 

* alcoholic liver disease (HR = 0.559; 95% CI: 0.347, 0.833; p = 4.3 × 10−3), 

* liver failure (HR = 0.548; 95% CI: 0.343, 0.875; p = 1.2 × 10−2), and 

* non-alcoholic liver disease (HR = 0.784; 95% CI: 0.650, 0.944; p = 1.0 × 10−2). 

Interestingly, we were able to replicate the association with reduced risk of NAFLD in a subset with liver MRIs (HR = 0.846; 95% CI: 0.777, 0.921; p = 1.1 × 10−4). In particular, women benefited from Omega-3 supplementation as well as heterozygous allele carriers of the liver-damaging variant PNPLA3 rs738409.

Conclusions: Omega-3 supplementation may reduce the incidence of liver disease. Our study highlights the potential of personalized treatment strategies for individuals at risk of metabolic liver disease. Further evaluation in clinical trials is warranted before Omega-3 can be recommended for the prevention of liver disease.

 **&lt;i class=&quot;fas fa-file-pdf&quot; style=&quot;margin-right: 0.3em;&quot;&gt;&lt;/i&gt;&lt;a href=&quot;https://d1bk1kqxc0sym.cloudfront.net/attachments/pdf/omega-3-liver-compresspdf.pdf&quot;&gt;Download the PDF from VitaminDWiki &lt;/a&gt;** 


AST Structure:
-------------
├── DivNode
│   full_match: `{DIV(class=&quot;lefth4&quot;)}{maketoc Title=&quot;&quot;}{DIV}`
│   inner_content: `{maketoc Title=&quot;&quot;}`
│   attrs_dict:
│   │   raw_content: (class=&quot;lefth4&quot;)
│   │   class: lefth4
│   children:
│   ├── MakeTocNode
│   │   full_match: `{maketoc Title=&quot;&quot;}`
│   │   inner_content: ``
│   │   attrs_dict:
│   │   │   raw_content:  Title=&quot;&quot;
│   │   │   Title: ├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!Omega-3 intake is associated with liver disease protection`
│   inner_content: `Omega-3 intake is associated with liver disease protection`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `Omega-3 intake is associated with liver disease protection`
│   │   inner_content: `Omega-3 intake is associated with liver disease protection`├── TextNode
│   full_match: `\nFront. Public Health, Volume 11 - 2023 | https://doi.org/10.3389/fpubh.2023.1192099\n\r\nMara Sophie VellMara Sophie Vell1Kate Townsend CreasyKate Townsend Creasy2Eleonora ScorlettiEleonora Scorletti3Katharina Sophie Seeling Katharina Sophie Seeling1 Leonida Hehl Leonida Hehl1Miriam Daphne RendelMiriam Daphne Rendel1Kai Markus Schneider&amp;#x;Kai Markus Schneider1†Carolin Victoria Schneider, &amp;#x;Carolin Victoria Schneider1,3,4*†\n1Department of Medicine III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany\n2Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA, United States\n3Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States\n4The Institute for Translational Medicine and Therapeutics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States\n\n`
│   inner_content: `\nFront. Public Health, Volume 11 - 2023 | https://doi.org/10.3389/fpubh.2023.1192099\n\r\nMara Sophie VellMara Sophie Vell1Kate Townsend CreasyKate Townsend Creasy2Eleonora ScorlettiEleonora Scorletti3Katharina Sophie Seeling Katharina Sophie Seeling1 Leonida Hehl Leonida Hehl1Miriam Daphne RendelMiriam Daphne Rendel1Kai Markus Schneider&amp;#x;Kai Markus Schneider1†Carolin Victoria Schneider, &amp;#x;Carolin Victoria Schneider1,3,4*†\n1Department of Medicine III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany\n2Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA, United States\n3Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States\n4The Institute for Translational Medicine and Therapeutics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States\n\n`├── ImgNode
│   full_match: `{img type=&quot;attId&quot; attId=&quot;22086&quot; width=&quot;500&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  type=&quot;attId&quot; attId=&quot;22086&quot; width=&quot;500&quot;
│   │   type: attId
│   │   attId: 22086
│   │   width: 500├── TextNode
│   full_match: `\nBackground: Non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease are among the most common liver diseases worldwide, and there are currently no Food and Drug Administration (FDA)-approved treatments. Recent studies have focused on lifestyle changes to prevent and treat NAFLD. Omega-3 supplementation is associated with improved outcomes in patients with chronic liver disease. However, it is unclear whether Omega-3 supplementation can prevent the development of liver disease, particularly in individuals at an increased (genetic) risk.\n\nMethods: In this UK Biobank cohort study, we established a multivariate cox proportional hazards model for the risk of incident liver disease during an 11 year follow up time. We adjusted the model for diabetes, prevalent cardiovascular disorders, socioeconomic status, diet, alcohol consumption, physical activity, medication intake (insulin, biguanides, statins and aspirin), and baseline characteristics.\n\nResults: Omega-3 supplementation reduced the risk of \n`
│   inner_content: `\nBackground: Non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease are among the most common liver diseases worldwide, and there are currently no Food and Drug Administration (FDA)-approved treatments. Recent studies have focused on lifestyle changes to prevent and treat NAFLD. Omega-3 supplementation is associated with improved outcomes in patients with chronic liver disease. However, it is unclear whether Omega-3 supplementation can prevent the development of liver disease, particularly in individuals at an increased (genetic) risk.\n\nMethods: In this UK Biobank cohort study, we established a multivariate cox proportional hazards model for the risk of incident liver disease during an 11 year follow up time. We adjusted the model for diabetes, prevalent cardiovascular disorders, socioeconomic status, diet, alcohol consumption, physical activity, medication intake (insulin, biguanides, statins and aspirin), and baseline characteristics.\n\nResults: Omega-3 supplementation reduced the risk of \n`├── ListItemNode
│   full_match: `*incident liver disease (HR = 0.716; 95% CI: 0.639, 0.802; p = 7.6 × 10−9). `
│   inner_content: `incident liver disease (HR = 0.716; 95% CI: 0.639, 0.802; p = 7.6 × 10−9). `
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `incident liver disease (HR = 0.716; 95% CI: 0.639, 0.802; p = 7.6 × 10−9). `
│   │   inner_content: `incident liver disease (HR = 0.716; 95% CI: 0.639, 0.802; p = 7.6 × 10−9). `├── TextNode
│   full_match: `\nThis protective association was particularly evident for \n`
│   inner_content: `\nThis protective association was particularly evident for \n`├── ListItemNode
│   full_match: `*alcoholic liver disease (HR = 0.559; 95% CI: 0.347, 0.833; p = 4.3 × 10−3), `
│   inner_content: `alcoholic liver disease (HR = 0.559; 95% CI: 0.347, 0.833; p = 4.3 × 10−3), `
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `alcoholic liver disease (HR = 0.559; 95% CI: 0.347, 0.833; p = 4.3 × 10−3), `
│   │   inner_content: `alcoholic liver disease (HR = 0.559; 95% CI: 0.347, 0.833; p = 4.3 × 10−3), `├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*liver failure (HR = 0.548; 95% CI: 0.343, 0.875; p = 1.2 × 10−2), and `
│   inner_content: `liver failure (HR = 0.548; 95% CI: 0.343, 0.875; p = 1.2 × 10−2), and `
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `liver failure (HR = 0.548; 95% CI: 0.343, 0.875; p = 1.2 × 10−2), and `
│   │   inner_content: `liver failure (HR = 0.548; 95% CI: 0.343, 0.875; p = 1.2 × 10−2), and `├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*non-alcoholic liver disease (HR = 0.784; 95% CI: 0.650, 0.944; p = 1.0 × 10−2). `
│   inner_content: `non-alcoholic liver disease (HR = 0.784; 95% CI: 0.650, 0.944; p = 1.0 × 10−2). `
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `non-alcoholic liver disease (HR = 0.784; 95% CI: 0.650, 0.944; p = 1.0 × 10−2). `
│   │   inner_content: `non-alcoholic liver disease (HR = 0.784; 95% CI: 0.650, 0.944; p = 1.0 × 10−2). `├── TextNode
│   full_match: `\nInterestingly, we were able to replicate the association with reduced risk of NAFLD in a subset with liver MRIs (HR = 0.846; 95% CI: 0.777, 0.921; p = 1.1 × 10−4). In particular, women benefited from Omega-3 supplementation as well as heterozygous allele carriers of the liver-damaging variant PNPLA3 rs738409.\n\nConclusions: Omega-3 supplementation may reduce the incidence of liver disease. Our study highlights the potential of personalized treatment strategies for individuals at risk of metabolic liver disease. Further evaluation in clinical trials is warranted before Omega-3 can be recommended for the prevention of liver disease.\n`
│   inner_content: `\nInterestingly, we were able to replicate the association with reduced risk of NAFLD in a subset with liver MRIs (HR = 0.846; 95% CI: 0.777, 0.921; p = 1.1 × 10−4). In particular, women benefited from Omega-3 supplementation as well as heterozygous allele carriers of the liver-damaging variant PNPLA3 rs738409.\n\nConclusions: Omega-3 supplementation may reduce the incidence of liver disease. Our study highlights the potential of personalized treatment strategies for individuals at risk of metabolic liver disease. Further evaluation in clinical trials is warranted before Omega-3 can be recommended for the prevention of liver disease.\n`├── FontNode
│   full_match: `{FONT(size=&quot;17&quot;)}__{ATTACH(inline=&quot;1&quot; id=&quot;22085&quot; icon=&quot;1&quot;)}Download the PDF from VitaminDWiki {ATTACH}__{FONT}`
│   inner_content: `__{ATTACH(inline=&quot;1&quot; id=&quot;22085&quot; icon=&quot;1&quot;)}Download the PDF from VitaminDWiki {ATTACH}__`
│   attrs_dict:
│   │   raw_content: size=&quot;17&quot;
│   │   size: 17
│   children:
│   ├── BoldNode
│   │   full_match: `__{ATTACH(inline=&quot;1&quot; id=&quot;22085&quot; icon=&quot;1&quot;)}Download the PDF from VitaminDWiki {ATTACH}__`
│   │   inner_content: `{ATTACH(inline=&quot;1&quot; id=&quot;22085&quot; icon=&quot;1&quot;)}Download the PDF from VitaminDWiki {ATTACH}`
│   │   children:
│   │   ├── AttachNode
│   │   │   full_match: `{ATTACH(inline=&quot;1&quot; id=&quot;22085&quot; icon=&quot;1&quot;)}Download the PDF from VitaminDWiki {ATTACH}`
│   │   │   inner_content: `Download the PDF from VitaminDWiki `
│   │   │   attrs_dict:
│   │   │   │   raw_content: (inline=&quot;1&quot; id=&quot;22085&quot; icon=&quot;1&quot;)
│   │   │   │   inline: 1
│   │   │   │   id: 22085
│   │   │   │   icon: 1
│   │   │   children:
│   │   │   ├── TextNode
│   │   │   │   full_match: `Download the PDF from VitaminDWiki `
│   │   │   │   inner_content: `Download the PDF from VitaminDWiki `├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!VitaminDWiki -  {SQL(db=&gt;vitamind)}SELECT COUNT(*) FROM (SELECT catObjectId, COUNT(*) FROM `tiki_category_objects` WHERE categId = 14  OR categId = 122 GROUP BY catObjectId HAVING COUNT(*) &gt; 1) AS categs INNER JOIN tiki_objects ON tiki_objects.objectId = categs.catObjectId WHERE type = &quot;wiki page&quot;{SQL}       studies in both categories Liver and Omega-3`
│   inner_content: `VitaminDWiki -  {SQL(db=&gt;vitamind)}SELECT COUNT(*) FROM (SELECT catObjectId, COUNT(*) FROM `tiki_category_objects` WHERE categId = 14  OR categId = 122 GROUP BY catObjectId HAVING COUNT(*) &gt; 1) AS categs INNER JOIN tiki_objects ON tiki_objects.objectId = categs.catObjectId WHERE type = &quot;wiki page&quot;{SQL}       studies in both categories Liver and Omega-3`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `VitaminDWiki -  `
│   │   inner_content: `VitaminDWiki -  `
│   ├── SqlNode
│   │   full_match: `{SQL(db=&gt;vitamind)}SELECT COUNT(*) FROM (SELECT catObjectId, COUNT(*) FROM `tiki_category_objects` WHERE categId = 14  OR categId = 122 GROUP BY catObjectId HAVING COUNT(*) &gt; 1) AS categs INNER JOIN tiki_objects ON tiki_objects.objectId = categs.catObjectId WHERE type = &quot;wiki page&quot;{SQL}`
│   │   inner_content: `SELECT COUNT(*) FROM (SELECT catObjectId, COUNT(*) FROM `tiki_category_objects` WHERE categId = 14  OR categId = 122 GROUP BY catObjectId HAVING COUNT(*) &gt; 1) AS categs INNER JOIN tiki_objects ON tiki_objects.objectId = categs.catObjectId WHERE type = &quot;wiki page&quot;`
│   │   attrs_dict:
│   │   │   raw_content: db=&gt;vitamind
│   │   │   db: &gt;vitamind
│   ├── TextNode
│   │   full_match: `       studies in both categories Liver and Omega-3`
│   │   inner_content: `       studies in both categories Liver and Omega-3`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── EmphasisNode
│   full_match: `&#39;&#39;This list is automatically updated&#39;&#39;`
│   inner_content: `This list is automatically updated`
│   children:
│   ├── TextNode
│   │   full_match: `This list is automatically updated`
│   │   inner_content: `This list is automatically updated`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── CategoryNode
│   full_match: `{category id=&quot;14+122&quot; types=&quot;wiki&quot; sort=&quot;created_desc&quot; split=&quot;n&quot; and=&quot;y&quot; sub=&quot;n&quot;- showdescription=&quot;n&quot; showname=&quot;y&quot; showtype=&quot;n&quot; one=&quot;y&quot; showTitle=&quot;n&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content: id=&quot;14+122&quot; types=&quot;wiki&quot; sort=&quot;created_desc&quot; split=&quot;n&quot; and=&quot;y&quot; sub=&quot;n&quot;- showdescription=&quot;n&quot; showname=&quot;y&quot; showtype=&quot;n&quot; one=&quot;y&quot; showTitle=&quot;n&quot;
│   │   id: 14+122
│   │   types: wiki
│   │   sort: created_desc
│   │   split: n
│   │   and: y
│   │   sub: n
│   │   showdescription: n
│   │   showname: y
│   │   showtype: n
│   │   one: y
│   │   showTitle: n├── TextNode
│   full_match: `\n\n`
│   inner_content: `\n\n`├── TikiCommentNode
│   full_match: `~tc~ (alias(Imega-3 helps NAFLD and other liver problems -  July 2023)) ~/tc~`
│   inner_content: ` (alias(Imega-3 helps NAFLD and other liver problems -  July 2023)) `
│   children:
│   ├── TextNode
│   │   full_match: `(alias(Imega-3 helps NAFLD and other liver problems -  July 2023)) `
│   │   inner_content: `(alias(Imega-3 helps NAFLD and other liver problems -  July 2023)) `

Original Tiki:
-------------
{DIV(class=&quot;lefth4&quot;)}{maketoc Title=&quot;&quot;}{DIV}
---
!!!!Omega-3 intake is associated with liver disease protection
Front. Public Health, Volume 11 - 2023 | https://doi.org/10.3389/fpubh.2023.1192099
\r\nMara Sophie VellMara Sophie Vell1Kate Townsend CreasyKate Townsend Creasy2Eleonora ScorlettiEleonora Scorletti3Katharina Sophie Seeling Katharina Sophie Seeling1 Leonida Hehl Leonida Hehl1Miriam Daphne RendelMiriam Daphne Rendel1Kai Markus Schneider&amp;#x;Kai Markus Schneider1†Carolin Victoria Schneider, &amp;#x;Carolin Victoria Schneider1,3,4*†
1Department of Medicine III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany
2Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA, United States
3Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
4The Institute for Translational Medicine and Therapeutics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States

{img type=&quot;attId&quot; attId=&quot;22086&quot; width=&quot;500&quot;}
Background: Non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease are among the most common liver diseases worldwide, and there are currently no Food and Drug Administration (FDA)-approved treatments. Recent studies have focused on lifestyle changes to prevent and treat NAFLD. Omega-3 supplementation is associated with improved outcomes in patients with chronic liver disease. However, it is unclear whether Omega-3 supplementation can prevent the development of liver disease, particularly in individuals at an increased (genetic) risk.

Methods: In this UK Biobank cohort study, we established a multivariate cox proportional hazards model for the risk of incident liver disease during an 11 year follow up time. We adjusted the model for diabetes, prevalent cardiovascular disorders, socioeconomic status, diet, alcohol consumption, physical activity, medication intake (insulin, biguanides, statins and aspirin), and baseline characteristics.

Results: Omega-3 supplementation reduced the risk of 
*incident liver disease (HR = 0.716; 95% CI: 0.639, 0.802; p = 7.6 × 10−9). 
This protective association was particularly evident for 
*alcoholic liver disease (HR = 0.559; 95% CI: 0.347, 0.833; p = 4.3 × 10−3), 
*liver failure (HR = 0.548; 95% CI: 0.343, 0.875; p = 1.2 × 10−2), and 
*non-alcoholic liver disease (HR = 0.784; 95% CI: 0.650, 0.944; p = 1.0 × 10−2). 
Interestingly, we were able to replicate the association with reduced risk of NAFLD in a subset with liver MRIs (HR = 0.846; 95% CI: 0.777, 0.921; p = 1.1 × 10−4). In particular, women benefited from Omega-3 supplementation as well as heterozygous allele carriers of the liver-damaging variant PNPLA3 rs738409.

Conclusions: Omega-3 supplementation may reduce the incidence of liver disease. Our study highlights the potential of personalized treatment strategies for individuals at risk of metabolic liver disease. Further evaluation in clinical trials is warranted before Omega-3 can be recommended for the prevention of liver disease.
{FONT(size=&quot;17&quot;)}__{ATTACH(inline=&quot;1&quot; id=&quot;22085&quot; icon=&quot;1&quot;)}Download the PDF from VitaminDWiki {ATTACH}__{FONT}
---
!!!!VitaminDWiki -  {SQL(db=&gt;vitamind)}SELECT COUNT(*) FROM (SELECT catObjectId, COUNT(*) FROM `tiki_category_objects` WHERE categId = 14  OR categId = 122 GROUP BY catObjectId HAVING COUNT(*) &gt; 1) AS categs INNER JOIN tiki_objects ON tiki_objects.objectId = categs.catObjectId WHERE type = &quot;wiki page&quot;{SQL}       studies in both categories Liver and Omega-3
&#39;&#39;This list is automatically updated&#39;&#39;
{category id=&quot;14+122&quot; types=&quot;wiki&quot; sort=&quot;created_desc&quot; split=&quot;n&quot; and=&quot;y&quot; sub=&quot;n&quot;- showdescription=&quot;n&quot; showname=&quot;y&quot; showtype=&quot;n&quot; one=&quot;y&quot; showTitle=&quot;n&quot;}

~tc~ (alias(Imega-3 helps NAFLD and other liver problems -  July 2023)) ~/tc~
</code>
</pre></article></div></div><script src="/js/lightspa.js?v=1748176441"></script><script>const spa=new LightSPA({mainContentSelector:'[role="main"]',navigationSelector:"[data-spa-nav]"});window.search=new Search({documentsUrl:"/search/search_documents.json.gz?v=1748176441",indexUrl:"/search/search_index.json.gz?v=1748176441"}),document.addEventListener("DOMContentLoaded",function(){function e(e){var t=e.querySelector(".category-expander"),n=e.querySelector(".subcategory-list");e.classList.contains("collapsed")?(e.classList.remove("collapsed"),e.classList.add("expanded"),t.textContent="-",n.style.display="block"):(e.classList.remove("expanded"),e.classList.add("collapsed"),t.textContent="+",n.style.display="none")}document.querySelectorAll(".category-expander").forEach(function(t){t.addEventListener("click",function(t){t.stopPropagation();var n=this.closest(".top-level-category");e(n)})}),document.querySelectorAll(".category-name").forEach(function(t){t.addEventListener("click",function(t){t.stopPropagation();var n=this.closest(".top-level-category");e(n)})})})</script><script src="/js/toc-sanitizer.js?v=1748176441"></script><script src="/js/search-results-panel.js?v=1748176441"></script><script src="/js/tiki-redirects.js?v=1748176441"></script></body></html>